Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: Systematic review and meta-analysis

Journal of the Chinese Medical Association

Volumn 79, Issue 7, 2016, Pages 368-374

  Wang, Ning Tao ^a   Huang, Yi Shin ^b   Lin, Meng Hsien ^a   Huang, Bryan ^c   Perng, Chin Lin ^b   Lin, Han Chieh ^b  

^a Wei Gong Memorial Hospital   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

drug induced liver injury; hepatitis B; meta analysis; tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ISONIAZID; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS B; DISEASE ASSOCIATION; HUMAN; INCIDENCE; INFECTION RISK; SYSTEMATIC REVIEW; TOXIC HEPATITIS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPLICATION; META ANALYSIS; RISK;

ANTITUBERCULAR AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; HEPATITIS B, CHRONIC; HUMANS; RISK;

EID: 84995489221     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2015.12.006     Document Type: Article

References (29)

1. 1 Verma, S., Kaplowitz, N., Hepatotoxicity of antitubercular drugs. Kaplowitz, N., DeLeve, L.D., (eds.) Drug-induced liver disease, 3rd ed., 2013, Elsevier, London, 483–504.
2. 2 LiverTox, US National Library Medicine, NIH, NIDDK. Antituberculosis agents. Available at: http://livertox.nlm.nih.gov/AntituberculosisAgents.htm. [accessed 15.07.15].
3. 3 Huang, Y.S., Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc 77 (2014), 169–173.
4. 4 Saukkonen, J.J., Cohn, D.L., Jasmer, R.M., Schenker, S., Jereb, J.A., Nolan, C.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174 (2006), 935–952.
5. 5 Andrade, R.J., Robles, M., Fernández-Castañer, A., López-Ortega, S., López-Vega, M.C., Lucena, M.I., Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 13 (2007), 329–340.
6. 6 Fontana, R.J., Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 146 (2014), 914–928.
7. 7 Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Lai, S.L., Yang, S.Y., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of antituberculosis drug-induced hepatitis. Hepatology 35 (2002), 883–889.
8. 8 Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Chang, S.C., Chiang, C.H., et al. Cytochrome P450 2E1 genetic polymorphism and the susceptibility to anti-tuberculosis drug-induced hepatitis. Hepatology 37 (2003), 924–930.
9. 9 Wu, J.C., Lee, S.D., Yeh, P.F., Chan, C.Y., Wang, Y.J., Huang, Y.S., et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 98 (1990), 502–504.
10. 10 Wong, W.M., Wu, P.C., Yuen, M.F., Cheng, C.C., Yew, W.W., Wong, P.C., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31 (2000), 201–206.
11. 11 Patel, P.A., Voigt, M.D., Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 97 (2002), 1198–1203.
12. 12 Sun, H.Y., Chen, Y.J., Gau, C.S., Chang, S.C., Luh, K.T., A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. J Formos Med Assoc 108 (2009), 102–111.
13. 13 Wang, J.Y., Liu, C.H., Hu, F.C., Chang, H.C., Liu, J.L., Chen, J.M., et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 62 (2011), 448–455.
14. 14 McGlynn, K.A., Lustbader, E.D., Sharrar, R.G., Murphy, E.C., London, W.T., Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis 134 (1986), 666–668.
15. 15 Pan, L., Jia, Z.S., Chen, L., Fu, E.Q., Li, G.Y., Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol 11 (2005), 2518–2521.
16. 16 Hwang, S.J., Wu, J.C., Lee, C.N., Yen, F.S., Lu, C.J., Lin, T.P., et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 12 (1997), 87–91.
17. 17 Fernández-Villar, A., Sopeña, B., Vázquez, R., Ulloa, F., Fluiters, E., Mosteiro, M., et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 36 (2003), 293–298.
18. 18 Lee, B.H., Koh, W.J., Choi, M.S., Suh, G.Y., Chung, M.P., Kim, H., et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 127 (2005), 1304–1311.
19. 19 Chien, J.Y., Huang, R.M., Wang, J.Y., Ruan, S.Y., Chien, Y.J., Yu, C.J., et al. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 14 (2010), 616–621.
20. 20 Chan, P.C., Yang, C.H., Chang, L.Y., Wang, K.F., Lu, B.Y., Lu, C.Y., et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis 16 (2012), 633–638.
21. 21 Shu, C.C., Lee, C.H., Lee, M.C., Wang, J.Y., Yu, C.J., Lee, L.N., Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 17 (2013), 934–939.
22. 22 Lomtadze, N., Kupreishvili, L., Salakaia, A., Vashakidze, S., Sharvadze, L., Kempker, R.R., et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS ONE, 8, 2013, e83892.
23. 23 Shen, X., Yuan, Z., Mei, J., Zhang, Z., Guo, J., Wu, Z., et al. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law. Drug Saf 37 (2014), 43–51.
24. 24 Liu, Y.M., Cheng, Y.J., Li, Y.L., Liu, C.E., Hsu, W.H., Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis. Lung 192 (2014), 205–210.
25. 25 Centers for Disease Control, Ministry of Health and Welfare, Executive Yuan, Taiwan. Taiwan guidelines for TB diagnosis and treatment. 5th ed. Available at: http://www.cdc.gov.tw/infectionreportinfo.aspx?treeid=075874dc882a5bfd&nowtreeid=c6e4d08fdc49de51&tid=ED3E98C81FC2D3C2. [accessed 15.07.15].
26. 26 Bénichou, C., Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11 (1990), 272–276.
27. 27 Fontana, R.J., Watkins, P.B., Bonkovsky, H.L., Chalasani, N., Davern, T., Serrano, J., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Safety 32 (2009), 55–68.
28. 28 Chalasani, N., Bonkovsky, H.L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148 (2015), 1340–1352.
29. 29 Chih, L.H., On, A.W.F., Huang, Y.S., Correlation of antituberculosis drug-related liver injury and liver function monitoring: a 12-year experience in Taiwan Drug Relief Foundation. J Food Drug Anal 22 (2014), 356–362.